HYBRID EVENT: You can participate in person at Rome, Itlay or Virtually from your home or work.

11th Edition of International Conference on

Neurology and Neurological Disorders

June 05-07, 2025 | Rome, Italy

Neurology 2024

Impact of XBP1-mediated PINK1 transcriptional regulation to mitophagy control in parkinson’s disease

Speaker at Neurology and Neurological Disorders 2024 - Cristine Alves Da Costa
Institute of Molecular and Cellular Pharmacology, France
Title : Impact of XBP1-mediated PINK1 transcriptional regulation to mitophagy control in parkinson’s disease

Abstract:

Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons and the presence of intracellular inclusions, named Lewy bodies that are mainly composed of misfolded proteins. The accumulation of misfolded proteins is a molecular trigger of a cellular stress response in the endoplasmic reticulum (ER) called the Unfolded Protein Response (UPR). The modulation of the UPR has been demonstrated in post mortem studies of brain samples of patients affected by PD. Interestingly, PINK1 functionally interacts with several genes responsible for sporadic and genetic forms of PD, including PARKIN. PARKIN controls a key transcription factor of the UPR response, XBP1-S ("X-box binding protein 1-Spliced"). PARKIN also regulates the transcription of PINK1. This leads us to postulate that XBP1-S could be involved in the transcriptional regulation of PINK1, which would explain both the decrease in PINK1 mRNA and the failure of the mitophagic response in sporadic forms of PD.

Audience Take Away Notes:

  • The audience will learn about a new mechanism implicated in the regulation of a key Parkinson’s disease causative gene PINK1 and the impact of this regulation to ER stress control and PD development.

Biography:

Dr. Cristine Alves da Costa obtained a PhD in Toxicology from the Faculty of Pharmaceutical Sciences, USP, Brazil in 1997. Actually, Dr. Alves da Costa is a research director at INSERM and drives a team at the “Institute of Pharmacology Moléculaire et Cellulaire” (IPMC-CNRS). Her research interests include neurodegenerative diseases and brain tumors. Dr. Alves da Costa is currently is editor-in chief of Parkinson’s disease and editorial board member of Oncogene, Cells and Current Neuropharmacology. She has published more than 78 articles.

Watsapp